Personalised mRNA Cancer Vaccine Cuts Melanoma Recurrence
A personalised mRNA cancer vaccine developed by Moderna and Merck, when combined with the immunotherapy drug Keytruda, reduced the risk of melanoma recurrence or death by 42% and the risk of the disease spreading by 38%, according to results from a large-scale clinical trial announced by the two pharmaceutical companies. The trial involved more than …